|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar
|
|
2
|
Enzinger PC and Mayer RJ: Esophageal
cancer. N Engl J Med. 349:2241–2252. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pennathur A, Gibson MK, Jobe BA and
Luketich JD: Oesophageal carcinoma. Lancet. 381:400–412. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mariette C, Piessen G and Triboulet JP:
Therapeutic strategies in oesophageal carcinoma: Role of surgery
and other modalities. Lancet Oncol. 8:545–553. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cai XW, Yu WW, Yu W, Zhang Q, Feng W, Liu
MN, Sun MH, Xiang JQ, Zhang YW and Fu XL: Tissue-based quantitative
proteomics to screen and identify the potential biomarkers for
early recurrence/metastasis of esophageal squamous cell carcinoma.
Cancer Med. 7:2504–2517. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cooper JS, Guo MD, Herskovic A, Macdonald
JS, Martenson JA Jr, Al-Sarraf M, Byhardt R, Russell AH, Beitler
JJ, Spencer S, et al Radiation Therapy Oncology Group:
Chemoradiotherapy of locally advanced esophageal cancer: Long-term
follow-up of a prospective randomized trial (RTOG 85-01). JAMA.
281:1623–1627. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Natsugoe S, Ikeda M, Baba M, Churei H,
Hiraki Y, Nakajo M and Aikou T; Kyushu Study Group for Adjuvant
Therapy of Esophageal Cancer: Long-term survivors of advanced
esophageal cancer without surgical treatment: A multicenter
questionnaire survey in Kyushu, Japan. Dis Esophagus. 16:239–242.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ando N, Kato H, Igaki H, Shinoda M, Ozawa
S, Shimizu H, Nakamura T, Yabusaki H, Aoyama N, Kurita A, et al: A
randomized trial comparing postoperative adjuvant chemotherapy with
cisplatin and 5-fluorouracil versus preoperative chemotherapy for
localized advanced squamous cell carcinoma of the thoracic
esophagus (JCOG9907). Ann Surg Oncol. 19:68–74. 2012. View Article : Google Scholar
|
|
9
|
Dutton SJ, Ferry DR, Blazeby JM, Abbas H,
Dahle-Smith A, Mansoor W, Thompson J, Harrison M, Chatterjee A,
Falk S, et al: Gefitinib for oesophageal cancer progressing after
chemotherapy (COG): A phase 3, multicentre, double-blind,
placebo-controlled randomised trial. Lancet Oncol. 15:894–904.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Suntharalingam M, Winter K, Ilson D,
Dicker AP, Kachnic L, Konski A, Chakravarthy AB, Anker CJ, Thakrar
H, Horiba N, et al: Effect of the addition of cetuximab to
paclitaxel, cisplatin, and radiation therapy for patients with
esophageal cancer: The NRG Oncology RTOG 0436 phase 3 randomized
clinical trial. JAMA Oncol. 3:1520–1528. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hemmatzadeh M, Mohammadi H, Karimi M,
Musavishenas MH and Baradaran B: Differential role of microRNAs in
the pathogenesis and treatment of Esophageal cancer. Biomed
Pharmacother. 82:509–519. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lin DC, Wang MR and Koeffler HP: Genomic
and epigenomic aberrations in esophageal squamous cell carcinoma
and implications for patients. Gastroenterology. 154:374–389. 2018.
View Article : Google Scholar :
|
|
13
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen CZ: MicroRNAs as oncogenes and tumor
suppressors. N Engl J Med. 353:1768–1771. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Friedman RC, Farh KK, Burge CB and Bartel
DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome
Res. 19:92–105. 2009. View Article : Google Scholar :
|
|
16
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mataki H, Seki N, Mizuno K, Nohata N,
Kamikawaji K, Kumamoto T, Koshizuka K, Goto Y and Inoue H:
Dual-strand tumor-suppressor microRNA-145 (miR-145-5p and
miR-145-3p) coordinately targeted MTDH in lung squamous cell
carcinoma. Oncotarget. 7:72084–72098. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Matsushita R, Yoshino H, Enokida H, Goto
Y, Miyamoto K, Yonemori M, Inoguchi S, Nakagawa M and Seki N:
Regulation of UHRF1 by dual-strand tumor-suppressor microRNA-145
(miR-145-5p and miR-145-3p): Inhibition of bladder cancer cell
aggressiveness. Oncotarget. 7:28460–28487. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Goto Y, Kurozumi A, Arai T, Nohata N,
Kojima S, Okato A, Kato M, Yamazaki K, Ishida Y, Naya Y, et al:
Impact of novel miR-145-3p regulatory networks on survival in
patients with castration-resistant prostate cancer. Br J Cancer.
117:409–420. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yamada Y, Koshizuka K, Hanazawa T, Kikkawa
N, Okato A, Idichi T, Arai T, Sugawara S, Katada K, Okamoto Y, et
al: Passenger strand of miR-145-3p acts as a tumor-suppressor by
targeting MYO1B in head and neck squamous cell carcinoma. Int J
Oncol. 52:166–178. 2018.
|
|
21
|
Schwarz DS, Hutvágner G, Du T, Xu Z,
Aronin N and Zamore PD: Asymmetry in the assembly of the RNAi
enzyme complex. Cell. 115:199–208. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mah SM, Buske C, Humphries RK and
Kuchenbauer F: miRNA*: A passenger stranded in
RNA-induced silencing complex? Crit Rev Eukaryot Gene Expr.
20:141–148. 2010. View Article : Google Scholar
|
|
23
|
Liu WW, Meng J, Cui J and Luan YS:
Characterization and Function of MicroRNA*s in Plants.
Front Plant Sci. 8:22002017. View Article : Google Scholar
|
|
24
|
Osako Y, Seki N, Koshizuka K, Okato A,
Idichi T, Arai T, Omoto I, Sasaki K, Uchikado Y, Kita Y, et al:
Regulation of SPOCK1 by dual strands of pre-miR-150 inhibit cancer
cell migration and invasion in esophageal squamous cell carcinoma.
J Hum Genet. 62:935–944. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sachdeva M and Mo YY: MicroRNA-145
suppresses cell invasion and metastasis by directly targeting mucin
1. Cancer Res. 70:378–387. 2010. View Article : Google Scholar :
|
|
26
|
Kano M, Seki N, Kikkawa N, Fujimura L,
Hoshino I, Akutsu Y, Chiyomaru T, Enokida H, Nakagawa M and
Matsubara H: miR-145, miR-133a and miR-133b: Tumor-suppressive
miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J
Cancer. 127:2804–2814. 2010. View Article : Google Scholar
|
|
27
|
Nishihira T, Hashimoto Y, Katayama M, Mori
S and Kuroki T: Molecular and cellular features of esophageal
cancer cells. J Cancer Res Clin Oncol. 119:441–449. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Osako Y, Seki N, Kita Y, Yonemori K,
Koshizuka K, Kurozumi A, Omoto I, Sasaki K, Uchikado Y, Kurahara H,
et al: Regulation of MMP13 by antitumor microRNA-375 markedly
inhibits cancer cell migration and invasion in esophageal squamous
cell carcinoma. Int J Oncol. 49:2255–2264. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yonemori K, Seki N, Kurahara H, Osako Y,
Idichi T, Arai T, Koshizuka K, Kita Y, Maemura K and Natsugoe S:
ZFP36L2 promotes cancer cell aggressiveness and is regulated by
antitumor microRNA-375 in pancreatic ductal adenocarcinoma. Cancer
Sci. 108:124–135. 2017. View Article : Google Scholar :
|
|
30
|
Yoshino H, Chiyomaru T, Enokida H,
Kawakami K, Tatarano S, Nishiyama K, Nohata N, Seki N and Nakagawa
M: The tumour-suppressive function of miR-1 and miR-133a targeting
TAGLN2 in bladder cancer. Br J Cancer. 104:808–818. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Harada K, Baba Y, Ishimoto T, Kosumi K,
Tokunaga R, Izumi D, Ohuchi M, Nakamura K, Kiyozumi Y, Kurashige J,
et al: Suppressor microRNA-145 is epigenetically regulated by
promoter hypermethylation in esophageal squamous cell carcinoma.
Anticancer Res. 35:4617–4624. 2015.PubMed/NCBI
|
|
32
|
Kita Y, Nishizono Y, Okumura H, Uchikado
Y, Sasaki K, Matsumoto M, Setoyama T, Tanoue K, Omoto I, Mori S, et
al: Clinical and biological impact of cyclin-dependent kinase
subunit 2 in esophageal squamous cell carcinoma. Oncol Rep.
31:1986–1992. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zeng JF, Ma XQ, Wang LP and Wang W:
MicroRNA-145 exerts tumor-suppressive and chemo-resistance lowering
effects by targeting CD44 in gastric cancer. World J Gastroenterol.
23:2337–2345. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sachdeva M, Zhu S, Wu F, Wu H, Walia V,
Kumar S, Elble R, Watabe K and Mo YY: p53 represses c-Myc through
induction of the tumor suppressor miR-145. Proc Natl Acad Sci USA.
106:3207–3212. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Arai T, Okato A, Yamada Y, Sugawara S,
Kurozumi A, Kojima S, Yamazaki K, Naya Y, Ichikawa T and Seki N:
Regulation of NCAPG by miR-99a-3p (passenger strand) inhibits
cancer cell aggressiveness and is involved in CRPC. Cancer Med.
7:1988–2002. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Idichi T, Seki N, Kurahara H, Fukuhisa H,
Toda H, Shimonosono M, Okato A, Arai T, Kita Y, Mataki Y, et al:
Molecular pathogenesis of pancreatic ductal adenocarcinoma: Impact
of passenger strand of pre-miR-148a on gene regulation. Cancer Sci.
109:2013–2026. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chen GM, Zheng AJ, Cai J, Han P, Ji HB and
Wang LL: microRNA-145-3p inhibits non-small cell lung cancer cell
migration and invasion by targeting PDK1 via the mTOR signaling
pathway. J Cell Biochem. 119:885–895. 2018. View Article : Google Scholar
|
|
38
|
Dutertre S, Descamps S and Prigent C: On
the role of aurora-A in centrosome function. Oncogene.
21:6175–6183. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fung TK, Yam CH and Poon RY: The
N-terminal regulatory domain of cyclin A contains redundant
ubiquitination targeting sequences and acceptor sites. Cell Cycle.
4:1411–1420. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li JY, Daniels G, Wang J and Zhang X:
TBL1XR1 in physiological and pathological states. Am J Clin Exp
Urol. 3:13–23. 2015.PubMed/NCBI
|
|
41
|
Liu L, Lin C, Liang W, Wu S, Liu A, Wu J,
Zhang X, Ren P, Li M and Song L: TBL1XR1 promotes lymphangiogenesis
and lymphatic metastasis in esophageal squamous cell carcinoma.
Gut. 64:26–36. 2015. View Article : Google Scholar
|
|
42
|
Tamotsu K, Okumura H, Uchikado Y, Kita Y,
Sasaki K, Omoto I, Owaki T, Arigami T, Uenosono Y, Nakajo A, et al:
Correlation of Aurora-A expression with the effect of
chemoradiation therapy on esophageal squamous cell carcinoma. BMC
Cancer. 15:3232015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhang HF, Alshareef A, Wu C, Jiao JW,
Sorensen PH, Lai R, Xu LY and Li EM: miR-200b induces cell cycle
arrest and represses cell growth in esophageal squamous cell
carcinoma. Carcinogenesis. 37:858–869. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Gabrielli F, Donadel G, Bensi G, Heguy A
and Melli M: A nuclear protein, synthesized in growth-arrested
human hepa-toblastoma cells, is a novel member of the short-chain
alcohol dehydrogenase family. Eur J Biochem. 232:473–477. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gabrielli F and Tofanelli S: Molecular and
functional evolution of human DHRS2 and DHRS4 duplicated genes.
Gene. 511:461–469. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Deisenroth C, Thorner AR, Enomoto T, Perou
CM and Zhang Y: Mitochondrial Hep27 is a c-Myb target gene that
inhibits Mdm2 and stabilizes p53. Mol Cell Biol. 30:3981–3993.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhou Y, Wang L, Ban X, Zeng T, Zhu Y, Li
M, Guan XY and Li Y: DHRS2 inhibits cell growth and motility in
esophageal squamous cell carcinoma. Oncogene. 37:1086–1094. 2018.
View Article : Google Scholar :
|
|
48
|
Wessels D, Murray J, Jung G, Hammer JA III
and Soll DR: Myosin IB null mutants of Dictyostelium exhibit
abnormalities in motility. Cell Motil Cytoskeleton. 20:301–315.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ohmura G, Tsujikawa T, Yaguchi T, Kawamura
N, Mikami S, Sugiyama J, Nakamura K, Kobayashi A, Iwata T, Nakano
H, et al: Aberrant Myosin 1b Expression Promotes Cell Migration and
Lymph Node Metastasis of HNSCC. Mol Cancer Res. 13:721–731. 2015.
View Article : Google Scholar
|
|
50
|
Elowe S: Bub1 and BubR1: At the interface
between chromosome attachment and the spindle checkpoint. Mol Cell
Biol. 31:3085–3093. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Athanasoula KC, Gogas H, Polonifi K,
Vaiopoulos AG, Polyzos A and Mantzourani M: Survivin beyond
physiology: Orchestration of multistep carcinogenesis and
therapeutic potentials. Cancer Lett. 347:175–182. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Aytes A, Mitrofanova A, Lefebvre C,
Alvarez MJ, Castillo-Martin M, Zheng T, Eastham JA, Gopalan A,
Pienta KJ, Shen MM, et al: Cross-species regulatory network
analysis identifies a synergistic interaction between FOXM1 and
CENPF that drives prostate cancer malignancy. Cancer Cell.
25:638–651. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Asghar U, Witkiewicz AK, Turner NC and
Knudsen ES: The history and future of targeting cyclin-dependent
kinases in cancer therapy. Nat Rev Drug Discov. 14:130–146. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Chen T, Sun Y, Ji P, Kopetz S and Zhang W:
Topoisomerase IIα in chromosome instability and personalized cancer
therapy. Oncogene. 34:4019–4031. 2015. View Article : Google Scholar
|
